Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report / Benedetto Caroleo, Alberto Migliore, Erika Cione, Stefania Zampogna, Francesco Perticone, Giovambattista De Sarro, Luca Gallelli
Background: Either direct or indirect tumor necrosis factor (TNF)-alpha blockers are usually used to treat psoriatic arthritis (PA), but their use can increase susceptibility to infectious diseases. Case Presentation: We report a rare case of double skin-knee wound and lung non-tubercular infection in a patient with PA under TNF-alpha blockers therapy. About 1 year after the beginning of adalimumab, a 48-year-old smoker suffering of PA was hospitalized for the skin-knee wound. Results: Clinical evaluation and biochemical markers excluded the presence of a systemic disease, and a skin infection sustained by leishmaniasis probably related to adalimumab was diagnosed (Naranjo score: 6). Adalimumab was discontinued and oral treatment with apremilast and topical treatment with meglumine antimoniate was started with a complete remission of skin wound in 2 weeks. About 7 months later when the patient was under apremilast treatment, he presented to our observation for dyspnea, cough and fever. High-Resolution Computer Tomography (HRCT) chest highlighted alveolar involvement with centrilobular small nodules, branching linear and nodular opacities. Microbiological culture of both broncho-alveolar lavage fluid and sputum documented an infection sustained by nontuberculous mycobacteria. Even if apremilast treatment probably-induced lung infection, we can’t exclude that it worsened a clinical condition induced by adalimumab. Apremilast was stopped and an empirical antitubercular treatment was started. Patient's breathlessness and cough improved as confirmed also by HRCT chest. Conclusion: This case highlights the importance to consider the possibility to develop leishmaniasis and/or non-tubercular mycobacterial infection in patients treated with TNF-alpha inhibitors.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Current drug safety - 14(2019), 2, Seite 147- |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Caroleo, Benedetto [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Umfang: |
1 Online-Ressource (4 p) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
KFL009016732 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL009016732 | ||
003 | DE-627 | ||
005 | 20231128152905.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220323s2019 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)KFL009016732 | ||
035 | |a (KFL)prod_DARH_.D4B7D321E90FB876C9928BDB085960C9BFBD7360 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Caroleo, Benedetto |e verfasserin |4 aut | |
245 | 1 | 0 | |a Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report |c Benedetto Caroleo, Alberto Migliore, Erika Cione, Stefania Zampogna, Francesco Perticone, Giovambattista De Sarro, Luca Gallelli |
264 | 1 | |c 2019 | |
300 | |a 1 Online-Ressource (4 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: Either direct or indirect tumor necrosis factor (TNF)-alpha blockers are usually used to treat psoriatic arthritis (PA), but their use can increase susceptibility to infectious diseases. Case Presentation: We report a rare case of double skin-knee wound and lung non-tubercular infection in a patient with PA under TNF-alpha blockers therapy. About 1 year after the beginning of adalimumab, a 48-year-old smoker suffering of PA was hospitalized for the skin-knee wound. Results: Clinical evaluation and biochemical markers excluded the presence of a systemic disease, and a skin infection sustained by leishmaniasis probably related to adalimumab was diagnosed (Naranjo score: 6). Adalimumab was discontinued and oral treatment with apremilast and topical treatment with meglumine antimoniate was started with a complete remission of skin wound in 2 weeks. About 7 months later when the patient was under apremilast treatment, he presented to our observation for dyspnea, cough and fever. High-Resolution Computer Tomography (HRCT) chest highlighted alveolar involvement with centrilobular small nodules, branching linear and nodular opacities. Microbiological culture of both broncho-alveolar lavage fluid and sputum documented an infection sustained by nontuberculous mycobacteria. Even if apremilast treatment probably-induced lung infection, we can’t exclude that it worsened a clinical condition induced by adalimumab. Apremilast was stopped and an empirical antitubercular treatment was started. Patient's breathlessness and cough improved as confirmed also by HRCT chest. Conclusion: This case highlights the importance to consider the possibility to develop leishmaniasis and/or non-tubercular mycobacterial infection in patients treated with TNF-alpha inhibitors | ||
700 | 1 | |a Migliore, Alberto |e verfasserin |4 aut | |
700 | 1 | |a Cione, Erika |e verfasserin |4 aut | |
700 | 1 | |a Zampogna, Stefania |e verfasserin |4 aut | |
700 | 1 | |a Perticone, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Sarro, Giovambattista De |e verfasserin |4 aut | |
700 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current drug safety |d Sharjah : Bentham Science Publ., 2006 |g 14(2019), 2, Seite 147- |h Online-Ressource |w (DE-627)KFL000006491 |w (DE-600)2235202-8 |w (DE-576)306833492 |x 2212-3911 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2019 |g number:2 |g pages:147- |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8863&volume=14&issue=2&spage=147 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-BEJ | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
935 | |i IMPORT_0628_prod_DARH_01 | ||
951 | |a AR | ||
952 | |d 14 |j 2019 |e 2 |h 147- |